B
Bull
Bull · 25%CMND
$0.98
シナリオ価格
$1.830
-0.104 (-5.67%)終値時点
Loading chart…
- High
- 1.930
- Open
- 1.930
- VWAP
- 1.84
- Vol
- 221.47K
- Mkt Cap
- 4.44M
- Low
- 1.760
- Amount
- 407.50K
- EV/EBITDA, TTM
- 0.00
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.
AI analysis of Clearmind Medicine Inc (CMND)
holdClearmind Medicine Inc is currently trading at $1.76, which is significantly down 91.16% year-to-date and 99.58% over the past year, indicating a strong decline in value. The stock has a current RSI of 49.87, suggesting it is neither overbought nor oversold, but the negative earnings per share (EPS) of -328.38 and a forward P/E ratio of 0 indicate ongoing financial struggles. While recent news about patent applications for MDMA combinations shows potential for future growth, the risks associated with its current financial performance and lack of profitability make it a hold rather than a buy at this time.
バリュエーション指標
The current forward P/E ratio for Clearmind Medicine Inc (CMND) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for CMND
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
イベントタイムライン
ニュース
9.009-01NewsfilterClearmind Initiates Phase IIa Trial for AUD Treatment
9.009-01NASDAQ.COMClearmind Initiates Phase 2a Study for CMND-100 in Alcohol Use Disorder
8.508-24NASDAQ.COMSciSparc and Clearmind Advance Patent Application for MDMA-PEA Combination
- 8.508-24Newsfilter
Clearmind's Patent Application for MDMA Combination Published
- 9.008-13Newsfilter
Clearmind Medicine Advances Clinical Trial for AUD Treatment
CMND FAQ — answered by Alphio AI
Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Clearmind Medicine Inc is currently trading at $1.76, which is significantly down 91.16% year-to-date and 99.58% over the past year, indicating a strong decline in value. The stock has a current RSI of 49.87, suggesting it is neither overbought nor oversold, but the negative earnings per share (EPS) of -328.38 and a forward P/E ratio of 0 indicate ongoing financial struggles. While recent news about patent applications for MDMA combinations shows potential for future growth, the risks associated with its current financial performance and lack of profitability make it a hold rather than a buy at this time.
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。